See analyst estimates and all valuation multiples for Drug Delivery Systems
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $18.4B | 8.4x | 38.1x | |
| $6.5B | 5.2x | 21.8x | |
| $3.6B | 3.4x | 12.8x | |
| $3.0B | 14.1x | 45.0x | |
| $2.6B | n/a | n/a | |
| $2.2B | 16.3x | -2.2x | |
| $1.3B | 4.3x | n/a | |
| $1.1B | 50.0x | n/a | |
| $1.1B | 12.7x | -24.8x | |
| $887M | 13.5x | -4.9x | |
| $503M | 24.2x | -74.4x | |
| $335M | 6.7x | 112.5x | |
| $333M | n/a | n/a | |
| $201M | n/a | n/a | |
| $189M | 5.6x | -8.1x | |
| $158M | 44.5x | -1.0x | |
| $149M | n/a | n/a | |
| $137M | 1.6x | n/a | |
| $113M | 32.9x | -4.4x | |
| $107M | 2.2x | -1.9x | |
| $107M | n/a | n/a | |
| $88.3M | n/a | n/a | |
| $70.6M | 390.3x | n/a | |
| $64.3M | 16.6x | -3.0x | |
| $63.0M | 3.4x | -24.8x | |
| $62.6M | n/a | n/a | |
| $49.6M | 10.6x | n/a | |
| $43.4M | 1.2x | 2.3x | |
| $43.3M | 54.3x | -0.8x | |
| $42.4M | 29.8x | -1.4x | |
| $38.3M | 7.7x | -8.4x | |
| $26.3M | n/a | n/a | |
| $24.0M | 38.7x | n/a | |
| $20.0M | n/a | n/a | |
| $19.0M | n/a | n/a | |
| $16.8M | 36.0x | n/a | |
| $14.6M | n/a | n/a | |
| $14.6M | 2.4x | n/a | |
| $11.2M | n/a | n/a | |
| $7.9M | 3.6x | n/a | |
| $6.4M | n/a | -0.4x | |
| $0.3M | n/a | n/a | |
| -$4.9M | -0.6x | n/a | |
| -$14.8M | n/a | n/a | |
| -$48.8M | n/a | n/a | |
| -$63.0M | -0.4x | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Drug Delivery Systems